IL124454A - Injectable danofloxacin formulations - Google Patents

Injectable danofloxacin formulations

Info

Publication number
IL124454A
IL124454A IL12445496A IL12445496A IL124454A IL 124454 A IL124454 A IL 124454A IL 12445496 A IL12445496 A IL 12445496A IL 12445496 A IL12445496 A IL 12445496A IL 124454 A IL124454 A IL 124454A
Authority
IL
Israel
Prior art keywords
danofloxacin
injectable
formulations
injectable danofloxacin
danofloxacin formulations
Prior art date
Application number
IL12445496A
Other languages
English (en)
Other versions
IL124454A0 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21735307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL124454(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of IL124454A0 publication Critical patent/IL124454A0/xx
Publication of IL124454A publication Critical patent/IL124454A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL12445496A 1995-12-21 1996-11-13 Injectable danofloxacin formulations IL124454A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US905295P 1995-12-21 1995-12-21
PCT/IB1996/001217 WO1997023217A1 (fr) 1995-12-21 1996-11-13 Formulations de quinolone injectables

Publications (2)

Publication Number Publication Date
IL124454A0 IL124454A0 (en) 1998-12-06
IL124454A true IL124454A (en) 2003-10-31

Family

ID=21735307

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12445496A IL124454A (en) 1995-12-21 1996-11-13 Injectable danofloxacin formulations

Country Status (42)

Country Link
US (1) US5811130A (fr)
EP (1) EP0868183B1 (fr)
JP (1) JP3416145B2 (fr)
KR (1) KR100402570B1 (fr)
CN (1) CN1104899C (fr)
AP (1) AP706A (fr)
AR (1) AR005147A1 (fr)
AT (1) ATE212551T1 (fr)
AU (1) AU709474B2 (fr)
BG (1) BG63933B1 (fr)
BR (1) BR9612230A (fr)
CA (1) CA2239352C (fr)
CO (1) CO4480098A1 (fr)
CZ (1) CZ293747B6 (fr)
DE (1) DE69618987T2 (fr)
DK (1) DK0868183T3 (fr)
DZ (1) DZ2146A1 (fr)
EG (1) EG24071A (fr)
ES (1) ES2167609T3 (fr)
GT (1) GT199600098A (fr)
HR (1) HRP960607B1 (fr)
HU (1) HU227918B1 (fr)
IL (1) IL124454A (fr)
IS (1) IS2010B (fr)
MA (1) MA24035A1 (fr)
MX (1) MX9805026A (fr)
MY (1) MY117109A (fr)
NO (1) NO315734B1 (fr)
NZ (2) NZ320545A (fr)
OA (1) OA10697A (fr)
PE (1) PE25798A1 (fr)
PL (1) PL186795B1 (fr)
PT (1) PT868183E (fr)
RS (1) RS49523B (fr)
RU (1) RU2141827C1 (fr)
SI (1) SI0868183T1 (fr)
SK (1) SK284412B6 (fr)
TN (1) TNSN96163A1 (fr)
TW (1) TW449475B (fr)
UA (1) UA56151C2 (fr)
WO (1) WO1997023217A1 (fr)
ZA (1) ZA9610780B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID21415A (id) * 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
DE19937115A1 (de) 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
AU2001228454A1 (en) * 2000-01-13 2001-07-24 Merck Patent G.M.B.H Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary
CA2680475A1 (fr) * 2000-12-28 2002-07-11 Shigeyuki Takada Preparations a liberation soutenue
MXPA05000011A (es) * 2002-06-26 2005-04-08 Pharmacia Corp Formulacion parenteral liquida estable de parecoxib.
AU2005258398A1 (en) * 2004-07-02 2006-01-12 Daiichi Pharmaceutical Co., Ltd. Quinolone-containing medicinal composition
WO2006125132A2 (fr) * 2005-05-18 2006-11-23 Mpex Pharmaceuticals, Inc. Fluoroquinolones en aerosols et leurs utilisations
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
FR2896416B1 (fr) 2006-01-24 2010-08-13 Vetoquinol Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine
BRPI0707641A2 (pt) * 2006-02-10 2011-05-10 Pari Pharma Gmbh antibiàticos nebulizados para terapia de inalaÇço
US20070197548A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions
DE102006010642A1 (de) * 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Arzneimittelformulierungen, enthaltend Fluorchinolone
DE102006010643A1 (de) 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
MX2007009796A (es) * 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
PT2344129T (pt) 2008-10-07 2018-04-23 Horizon Orphan Llc Formulações de fluoroquinolona em aerossol para farmacocinética melhorada
SI2346509T1 (sl) 2008-10-07 2020-08-31 Horizon Orphan Llc Inhalacija levofloksacina za zmanjšanje vnetja pljuč
AU2010289326B2 (en) 2009-09-04 2015-09-24 Horizon Therapeutics U.S. Holding Llc Use of aerosolized levofloxacin for treating cystic fibrosis
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
JP6675396B2 (ja) 2015-06-02 2020-04-01 杏林製薬株式会社 水性液剤
CA2988092A1 (fr) 2015-06-02 2016-12-08 Kyorin Pharmaceutical Co., Ltd. Formulation liquide aqueuse
CA2987879A1 (fr) 2015-06-02 2016-12-08 Kyorin Pharmaceutical Co., Ltd. Medicament aqueux
CN110248643B (zh) * 2017-02-13 2023-11-24 拜耳动物保健有限责任公司 含普拉沙星的液体组合物
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3517709A1 (de) * 1985-01-05 1986-07-10 Bayer Ag Basische zubereitungen von chinoloncarbonsaeuren
JPS63188626A (ja) * 1987-01-30 1988-08-04 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸の可溶化方法
DE3902079A1 (de) * 1988-04-15 1989-10-26 Bayer Ag I.m. injektionsformen von gyrase-inhibitoren
CA2072366C (fr) * 1989-12-29 2002-08-20 Laman A. Al-Razzak Complexes d'acide carboxylique d'une quinolone-ion d'un metal-acide
US5084276A (en) * 1990-01-05 1992-01-28 Abbott Laboratories Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation
EP0443381B2 (fr) * 1990-02-14 1997-10-22 Takeda Chemical Industries, Ltd. Composition effervescente, sa production et son utilisation
FR2665635A1 (fr) * 1990-08-10 1992-02-14 Merck Sharp & Dohme Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
US5082863A (en) * 1990-08-29 1992-01-21 Schering Corporation Pharmaceutical composition of florfenicol
US5235054A (en) * 1992-07-15 1993-08-10 Pfizer Inc. 3-carboxaldehyde substituted quinolines and naphthyridines
JPH0782141A (ja) * 1993-09-17 1995-03-28 Tanabe Seiyaku Co Ltd 動物用注射剤

Also Published As

Publication number Publication date
DE69618987T2 (de) 2002-11-21
CZ193098A3 (cs) 1999-05-12
EG24071A (en) 2008-05-11
CO4480098A1 (es) 1997-07-09
UA56151C2 (uk) 2003-05-15
PL186795B1 (pl) 2004-02-27
KR19990076617A (ko) 1999-10-15
ES2167609T3 (es) 2002-05-16
WO1997023217A1 (fr) 1997-07-03
YU69096A (sh) 1999-06-15
EP0868183B1 (fr) 2002-01-30
CA2239352C (fr) 2002-06-04
IS4755A (is) 1998-05-25
AP706A (en) 1998-12-04
BG63933B1 (bg) 2003-07-31
KR100402570B1 (ko) 2003-12-18
US5811130A (en) 1998-09-22
MA24035A1 (fr) 1997-07-01
EP0868183A1 (fr) 1998-10-07
NZ501160A (en) 2001-10-26
PE25798A1 (es) 1998-05-21
NO982842D0 (no) 1998-06-19
JPH11501331A (ja) 1999-02-02
HRP960607B1 (en) 2002-06-30
GT199600098A (es) 1998-06-12
CN1205636A (zh) 1999-01-20
JP3416145B2 (ja) 2003-06-16
ZA9610780B (en) 1998-06-22
NO315734B1 (no) 2003-10-20
PT868183E (pt) 2002-06-28
AU709474B2 (en) 1999-08-26
CZ293747B6 (cs) 2004-07-14
PL328001A1 (en) 1999-01-04
BG102542A (en) 1999-06-30
OA10697A (en) 2001-05-04
SK284412B6 (sk) 2005-03-04
AU7328996A (en) 1997-07-17
IL124454A0 (en) 1998-12-06
DK0868183T3 (da) 2002-03-25
ATE212551T1 (de) 2002-02-15
NZ320545A (en) 2000-03-27
HUP9903726A3 (en) 2001-01-29
AP9600898A0 (en) 1997-01-31
RS49523B (sr) 2006-10-27
HRP960607A2 (en) 1998-06-30
AR005147A1 (es) 1999-04-14
HU227918B1 (en) 2012-06-28
DZ2146A1 (fr) 2002-10-23
SI0868183T1 (en) 2002-04-30
IS2010B (is) 2005-05-13
TNSN96163A1 (fr) 2005-03-15
MX9805026A (es) 1998-09-30
DE69618987D1 (de) 2002-03-14
CA2239352A1 (fr) 1997-07-03
MY117109A (en) 2004-05-31
CN1104899C (zh) 2003-04-09
NO982842L (no) 1998-06-19
RU2141827C1 (ru) 1999-11-27
TW449475B (en) 2001-08-11
SK80798A3 (en) 1999-09-10
HUP9903726A2 (hu) 2000-04-28
BR9612230A (pt) 1999-07-13

Similar Documents

Publication Publication Date Title
IL124454A (en) Injectable danofloxacin formulations
GB2326093B (en) Avermectin formulation
HUP9902853A3 (en) Syringes
GB9513261D0 (en) Vaccines
GB2308302B (en) Syringe
EG20812A (en) Syringes
GB9609203D0 (en) Formulations
GB9524722D0 (en) Syringes
GB9418550D0 (en) Drug formulation
HU9602732D0 (en) Lanperisone formulation
CA77371S (en) Ampoule
GB9524151D0 (en) Syringes
GB9524458D0 (en) Syringe
GB9513871D0 (en) Syringe
GB9511410D0 (en) Syringe
IL114370A0 (en) Syringe
GB2329335B (en) Medicament
GB9614326D0 (en) Medicament
GB9607355D0 (en) Syringes
GB9510349D0 (en) Formulations
GB9509941D0 (en) Formulations
GB9508144D0 (en) Formulations
GB9524825D0 (en) Vaccines
ZA962612B (en) Vaccines
GB9513443D0 (en) Vaccines

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees